The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Boron-Based Drug Design
Abstract
The use of the element boron, which is not generally observed in a living body, possesses a high potential for the discovery of new biological activity in pharmaceutical drug design. In this account, we describe our recent developments in boron-based drug design, including boronic acid containing protein tyrosine kinase inhibitors, proteasome inhibitors, and tubulin polymerization inhibitors, and ortho-carborane-containing proteasome activators, hypoxia-inducible factor 1 inhibitors, and topoisomerase inhibitors. Furthermore, we applied a closo-dodecaborate as a water-soluble moiety as well as a boron-10 source for the design of boron carriers in boron neutron capture therapy, such as boronated porphyrins and boron lipids for a liposomal boron delivery system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control · doi:10.1177/107327480301000502 · Cited by 292
Cited by
Cho, S., Hwang, S. Y., Oh, D. X., & Park, J. (2021) · Journal of Materials Chemistry A · doi:10.1039/d1ta02308j · Cited by 482
Challenges and Opportunities for the Application of Boron Clusters in Drug Design
Leśnikowski, Z. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01932 · Cited by 348
First-Row d-Block Element-Catalyzed Carbon–Boron Bond Formation and Related Processes
Bose, S. K., Mao, L., Kuehn, L., Radius, U., Nekvinda, J., Santos, W. L., Westcott, S. A., Steel, P. G., & Marder, T. B. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00255 · Cited by 327
Wang, P., Gong, Q., Hu, J., Li, X., & Zhang, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01704 · Cited by 270
Boron in drug design: Recent advances in the development of new therapeutic agents
Fernandes, G. F. S., Denny, W. A., & Dos Santos, J. L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.092 · Cited by 269
Metadata
- Authors
- Ban, H. S., & Nakamura, H.
- Venue
- The Chemical Record
- Publisher
- Wiley
- Published
- 2015-03-20
- Volume
- 15
- Issue
- 3
- Pages
- 616-635
- ISSN
- 1527-8999 (ISSN-L)
- OpenAlex
- W1924841364
- Cited by
- 167
- References
- 8
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Boron-Based Drug Design. https://app.cochat.ai/papers/10.1002/tcr.201402100
- The paper
- Ban, H. S., & Nakamura, H. (2015). Boron-Based Drug Design. The Chemical Record. https://doi.org/10.1002/tcr.201402100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.